BMRN Stock Analysis: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$59.20
0.08 (0.14%)
▲
5d:
+0.7%
30d:
+5.39%
90d:
+8.56%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 03, 2026
19d
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 0.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 0.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$118.17
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$73.37
19.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $59.20, which is considered extended relative to its 30-day fair value range of $55.72 to $58.95. The stock's valuation (Forward PE: 9.2) is in line with its historical norms (9.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $60.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $87.69 (+48.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $60.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $87.69 (+48.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$55.72 -
$58.95
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.1% below Wall St target ($87.69)
Trading Range Analysis
30-Day Trading Range
$55.72 -
$58.95
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$56.43
Resistance Level
$60.67
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.17
Wall Street Target
$87.69
(+48.1%)
Revenue Growth (YoY)
2.8%
Earnings Growth (YoY)
-43.1%
Profit Margin
8.3%
Valuation Discount vs History
-0.8% cheaper
PE vs Historical
9.2 vs 9.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.8%
(market-implied from PE analysis)
1-Year Target
$58.73
(-1%)
2-Year Target
$58.26
(-2%)
3-Year Target
$57.79
(-2%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
$59.24
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 30.7%)
$313.85
(+430%)
Base:
(SPY PE: 9.2, Growth: 30.7%)
$132.15
(+123%)
Bear:
(PE: 7.8, Growth: 30.7%)
$112.33
(+90%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (43x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 42.53 | Current EPS (TTM): $1.39
Bull Case
$130.06
(+120%)
Analyst growth 100.0%, PE expands to 46.8
Base Case
$118.24
(+100%)
Market implied 100.0%, PE stable at 42.5
Bear Case
$40.20
(-32%)
Severe decline -20.0%, PE contracts to 36.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.2 to 9.4
Stabilization Target:
$60.68
(+2.5%)
PE Expansion Potential:
+2.5%
Share & Embed Analysis
Last updated: July 14, 2026 12:33 AM ET
Data refreshes hourly during market hours. Next update: 1:33 AM
Data refreshes hourly during market hours. Next update: 1:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles Greg Guyer
SELL
16486 shares
2026-03-11
Gregory R Friberg
SELL
6326 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
